Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exscientia Ltd ADR (NQ: EXAI )

4.870 -0.180 (-3.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 433,834
Open 5.000
Bid (Size) 4.800 (1)
Ask (Size) 5.050 (4)
Prev. Close 5.050
Today's Range 4.760 - 5.025
52wk Range 3.800 - 7.910
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
From Exscientia plc
Via Business Wire
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024
From Exscientia plc
Via Business Wire

Performance

YTD
-22.14%
-22.14%
1 Month
-3.37%
-3.37%
3 Month
-9.31%
-9.31%
6 Month
+11.19%
+11.19%
1 Year
-11.93%
-11.93%

More News

Read More
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
Via Talk Markets
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
Via Talk Markets
Topics Economy
Exposures Economy
Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Exscientia plc
Via Business Wire
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
Via Talk Markets
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
Via The Motley Fool
EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Exscientia Business Update for Second Quarter and First Half 2024
From Exscientia plc
Via Business Wire
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
Via Talk Markets
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
From FN Media Group LLC
Via GlobeNewswire
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
Via Talk Markets
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
Via Talk Markets
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
From Exscientia plc
Via Business Wire
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
Via Talk Markets
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
From Exscientia plc
Via Business Wire
3 Small-Cap Stocks With Explosive 2X Growth Potential
Via InvestorPlace
Clinical-Stage BioTech Drug Stocks Declined 13% In June
Via Talk Markets
EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.